Distinct and Non-Cross-Reactive Epitopes are Recognized on B16 Melanoma by LAK Cells and Anti-B16 Monoclonal Antibodies

Abstract

Abstract

Two rat anti-B16 melanoma monoclonal antibodies (MoAb), designated IB16–6 and IB16–8, recognize an epitope expressed with high density on the surface of B16 parental cells and B16-F1, F10, F10FLR, and BL6 sublines. The purpose of this study was to define by means of cytolytic and clonogenic assays whether these MoAbs reacted with the same or distinct determinants as those recognized on B16 targets by lymphokine-activated killer (LAK) cells. Using ¹²⁵I-labeled antibody and Scatchard analysis, the affinity constant (K_A ) of IB16–6 was determined to range from 5.6 to 9.4 × 10⁵ liter/M and the number of receptor sites per B16 cell was 4.8 × 10⁴ to 2.5 × 10⁵. The effects of anti-B16 MoAb on LAK activity were determined by either preincubating ⁵¹Cr-labeled B16 target cells with varying concentrations of MoAb, followed by the cytolytic assay, or exposing unlabeled B16 cells to MoAb, and then carrying out a 10-day clonogenic assay. Over a wide range of antibody concentrations, IB16–6 and IB16–8 had minimal effects on LAK activity, and even at MoAb concentrations up to 1 mg there were no changes in target cell sensitivity or colony-forming ability. Enzymatic treatment of B16 melanoma cells with either trypsin or pronase completely removed the epitope recognized by MoAb IB16–6 but did not alter B16 sensitivity to LAK cells. These observations indicate that the LAK recognition unit was distinct from the epitope reactive with MoAb IB16–6 and that the B16 determinant(s) recognized by LAK cells is resistant to proteolytic enzymes. The molecular structure of each of these remains to be determined.